



Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "**Company**") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.

1.	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Markus Rohrwild	
2.	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification/ Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Gubra A/S	
b)	LEI	254900T17RRFZONO6W53	
4.1	Details of the transaction(s):		
a)	Description of the financial instrument, type of instrument	Shares (ISIN DK0062266474)	
	Identification code		
b)	Nature of the transaction	Acquisition of shares in connection with Gubra's Employee Share Purchase Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		358.52	1,312



d)	Aggregated information — Aggregated volume — Price	Average price per share: DKK 358.52 Total number of shares: 1,312 Total price: DKK 470,382
e)	Date of the transaction	16 June 2026
f)	Place of the transaction	NASDAQ Copenhagen

Contacts at Gubra

Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)

Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Adam Lange (adl@gubra.dk, +45 6646 1589)

About Gubra

Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra's activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around \$400 million) in 2025. See www.gubra.dk for more information.